An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new trial found that adding a drug called trevogrumab can stop people from losing muscle and other lean tissue when they lose weight on GLP-1 receptor agonists — the class of medicines that includes popular drugs like Ozempic and Wegovy. The report is from a Phase 2 study named COURAGE, and it says trevogrumab prevented the drop in lean mass that usually comes with the big weight loss people get on these GLP-1 drugs. Trevogrumab is an experimental therapy that targets a protein involved in regulating muscle growth. In plain terms, it acts on a pathway that helps your body keep muscle. GLP-1 receptor agonists are drugs that mimic a gut hormone to reduce appetite and slow stomach emptying, which makes people eat less and lose weight. Trevogrumab is meant to be used with those weight-loss drugs to protect muscle while someone loses fat. The study was a Phase 2 trial, which means it’s an early-stage human test mainly looking at whether the idea works and is reasonably safe. According to the report, people taking trevogrumab alongside a GLP-1 drug did not experience the same loss of lean mass that typically happens during rapid weight loss on GLP-1 therapy. The write-up doesn’t give exact numbers here, so we don’t know how big the effect was, how many people were in the study, or how long the benefit lasted. Phase 2 trials are promising but usually small, so the finding needs confirmation in larger Phase 3 trials. This matters because when people lose a lot of weight quickly, some of that loss is muscle, not just fat. Losing muscle can make you weaker, slow your metabolism, and make it easier to regain weight later. If a drug like trevogrumab truly preserves muscle during medically supervised weight loss, it could help people keep strength and possibly improve long-term outcomes from weight-loss therapy. That could be important for older adults, people with obesity-related muscle loss, or anyone worried about strength while losing weight. There are important caveats. Phase 2 results are preliminary. The report doesn’t disclose side effects, long-term safety, or whether trevogrumab affects other tissues. As an experimental drug it’s not widely approved for this use yet. Combining two medicines can add risks, and some people — for example those with certain medical conditions or taking particular medications — might not be candidates. We also don’t know if preserving lean mass translates into better long-term health or function; that needs more, larger studies. Bottom line: Early human trial results suggest trevogrumab may block muscle loss that often comes with powerful GLP-1 weight-loss drugs, but the evidence is preliminary and more research is needed to confirm safety and real-world benefit.
Source: Investing News Network